Roche
9115 Hague Road
Indianapolis
Indiana
46256
United States
Tel: 317-521-2000
Fax: 317-521-2090
Website: http://www.roche.com/
2062 articles with Roche
-
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended 14-1 that the two companies conduct a trial applicable to the U.S. population.
-
Novartis CEO Vas Narasimhan and Roche CEO Severin Schwan saw revenue growth for the past year, and each took home more than $12 million in total compensation for 2021.
-
To address that lack of diversity, Medable and CVS have forged a collaboration to improve patient access to clinical trial research.
-
In Roche’s 2021 annual report, the company detailed that group sales rose 9%, pharmaceutical sales up 3%, and diagnostics up a whopping 29%.
-
The decision came after the Phase IIb study results demonstrating a statistically significant decrease in non-HDL-C and statistically significant reductions in triglycerides and ANGPTL3.
-
The San Diego-based immunology company is locating and developing molecules where the mechanism of action has either been proven or makes sense.
-
Pazdur, along with the FDA’s R. Angelo de Claro and Gautam Mehta from the Center for Drug Evaluation and Research, penned an opinion piece published Thursday in JAMA Oncology.
-
Hal Barron, the man who guided the reinvigoration of the pharmaceutical direction at GSK, is departing the company to be the CEO of Altos Labs.
-
Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial
1/18/2022
Ionis Pharmaceuticals, Inc. announced that its partner, Roche, is designing a new Phase 2 trial to evaluate tominersen in Huntington's disease.
-
The decision to carry on came after dosing for the Phase III GENERATION HD1 trial was halted following an overall risk/benefit assessment.
-
The company’s vision for the next few years includes annual revenue of $5 billion by 2025 and the approval of at least five novel products by the end of the decade.
-
The Centers for Medicare and Medicaid Services indicated it would cover the cost of these drugs and any necessary scans — but only “if they are enrolled in qualifying clinical trials.”
-
Sarepta Therapeutics shared positive topline results from its ongoing SRP-9001-102 study on the effectiveness of delandistrogene moxeparvovec in treating Duchenne muscular dystrophy.
-
Roche’s investment is aimed at supporting the development of Freenome’s colorectal cancer detection technology.
-
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
-
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
-
Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders
12/20/2021
Lineage Cell Therapeutics, Inc., announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and license agreement with Roche and Genentech for the development and commercialization of a retinal pigment epithelium cell therapy for the treatment of ocular disorders, including advanced dry age-related macular degeneration with geographic atrophy.
-
Roche receives CE mark for the use of saliva samples with cobas SARS-CoV-2 Qualitative test on cobas 6800/8800 Systems
12/17/2021
Roche announced that its cobas® SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas® 6800/8800 Systems.
-
Roche launches the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark
12/15/2021
Roche announced the launch of the first infectious disease tests on the cobas® 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.